The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear¥1,137.92Fair value¥4,038.51Bull¥6,929.97
FairClose
52-week traded range
52W low ¥1,230.0052W high ¥3,184.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
Sumitomo Pharma Co.,Ltd. closed at ¥1,527.00, 62.2% below the consensus fair value of ¥4,038.51 drawn from 9 valuation models.
Financial DNA score 82/100 — Exceptional. P/E of 5.7x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
¥3,352.75
+119.6%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
¥2,040.34
+33.6%
√(22.5 × EPS × BVPS)
EPS=268.99, BVPS=687.84
P/E Fair Value
¥5,379.80
+252.3%
EPS × 20x (sector P/E)
EPS=268.99, Sector P/E=20x
Peter Lynch (PEG)
¥4,658.91
+205.1%
EPS × Growth% (PEG = 1 is fair)
EPS=268.99, g=17.3%
EV/EBITDA
¥4,956.29
+224.6%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=128.12B
Dividend Discount (DDM)
¥1,137.92
-25.5%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=21.07, r=10%, g=8%
Book Value (P/B)
¥6,929.97
+353.8%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=687.84, ROE=46.3%, g=6%, r=10%
Reverse DCF
¥1,527.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -10% | Historical: 17.3%
Margin of Safety
¥2,693.22
+76.4%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=3590.96, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.